Emergent BioSolutions | Zysk Brutto Na Sprzedaży





Zysk Brutto Na Sprzedaży Zmiana Data
Acadia Pharmaceuticals USD 256.99M 13.15M 2025-09
Akebia Therapeutics USD 49.21M 13.25M 2025-03
ALKERMES USD 265.83M 8.06M 2025-09
Alnylam Pharmaceuticals USD 829.31M 219.56M 2025-12
Amarin USD 22.21M 28.15M 2025-09
ANI Pharmaceuticals USD 111.79M 1.68M 2025-09
BioMarin Pharmaceutical USD 631.2M 39.27M 2025-09
Coherus Biosciences USD 4.95M 15.34M 2025-03
Exact Sciences USD 583.93M 21.48M 2025-09
Exelixis USD 572.18M 7M 2025-12
Glaxosmithkline GBP 8.75B 2.92B 2025-09
Heron Therapeutics USD 23.35M 1.6M 2024-09
Ionis Pharmaceuticals USD 155M 293M 2025-09
Ironwood Pharmaceuticals USD 85.24M 44.1M 2025-06
Lexicon Pharmaceuticals USD -16.16M 2.89M 2024-06
Lonza CHF 1.29B 248M 2025-06
Merck USD 13.42B 431M 2025-09
Moderna USD 226M 583M 2025-12
Myriad Genetics USD 143.8M 8M 2025-09
Nektar Therapeutics USD 13.75M 650K 2024-06
Neurocrine Biosciences USD 787.9M 7M 2025-12
Pacira USD 130.92M 5M 2025-09
Pfizer USD 3.54B 7.61B 2025-09
PTC Therapeutics USD 187.69M 24.3M 2025-09
Sanofi EUR 8.45B 1.31B 2025-12
Sarepta Therapeutics USD 247.9M 209.96M 2025-09
United Therapeutics USD 602.1M 108.9M 2025-09
Vanda Pharmaceuticals USD 50.6M 5.5M 2024-12
Xoma 992K 846K 2024-06


Emergent BioSolutions Zysk Brutto Na Sprzedaży - Aktualne wartości, dane historyczne, prognozy, statystyki, wykresy i kalendarz ekonomiczny - Feb 2026.